At what enterprise value was SEVETYS acquired in 2022?

During the acquisition of SEVETYS by EURAZEO in 2022, the company was valued at an estimated revenue multiple of below 5x. The transaction's Enterprise Value is estimated to be in the range of 500M - 1.5b EUR. By registering for free, you get access to complete and exact transaction details including enterprise value, revenue, and EBITDA. Additionally, our database shows that the Healthcare & Pharma industry currently tracks an average EBITDA multiple of 14.8x, providing a valuable benchmark for this transaction.

What was the EV/EBITDA of SEVETYS when it was acquired by EURAZEO?

The exact EV/EBITDA multiple for SEVETYS is available on mynth capital. For comparison, the Healthcare & Pharma sector currently shows an average EBITDA multiple of 14.8x. Join our community for free to access full valuation data and industry trends.

When was SEVETYS acquired by EURAZEO?

SEVETYS was acquired by EURAZEO in 2022.

What was the revenue of SEVETYS at the time of the deal?

The revenue of SEVETYS at the time of the deal is estimated to be in the range of 100M - 200M EUR. Register for free to access the full transaction report and exact valuation multiples.

What is Enterprise Value (EV)?

Enterprise Value (EV) is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

What is the EV/EBITDA multiple and why is it used?

The EV/EBITDA multiple is a financial ratio that compares a company's Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). It is widely used in M&A and valuation because it allows for comparisons between companies with different capital structures and provides a clear view of operational profitability.

How is the data for the SEVETYS acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the SEVETYS deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://fr.newsroom.eurazeo.com/actualites/eurazeo-annonce-son-entree-au-capital-de-sevetys-groupe-francais-detablissements-de-soins-veterinaires-ae37e-7ed35.html

← DATABASE

Home Database Healthcare & PharmaSEVETYS

06/2022

SEVETYS acquired by EURAZEO

FRANCE Health Providers / Outpatient Care / Vet Clinics EV 500M - 1.5b EUR

Context

Eurazeo acquired a majority stake in Sevetys from Ardian, which had previously financed the group's initial rapid expansion. The transaction included a EUR250 million equity injection from Eurazeo to fuel a new phase of aggressive growth. The investment thesis focuses on consolidating the highly fragmented French veterinary market, which is protected by specific regulatory barriers regarding clinical governance and independence. Sevetys positions itself as a sovereign French alternative to global giants like IVC Evidensia and AniCura. Under Eurazeo's ownership, the group successfully completed approximately 100 acquisitions in 2022 alone, expanding its footprint into new regions such as the Rhone Valley and Grenoble.

SEVETYS, which reported an EBITDA margin of LOGIN in 2022, is valued in this transaction at an EV/EBITDA multiple of LOGIN, a level to compare with the average currently observed in the Healthcare & Pharma sector (14.8x).

Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.

-> Deep-dive in Healthcare & Pharma market trends

Target

Founded in 2017, Sevetys is a leading French veterinary clinic group. It operates a network of over 150 sites across France, including major clusters inIle-de-France, Brittany, and the Loire Valley. The group differentiates itself through a "French model" of governance, ensuring that practicing veterinarians remain significant shareholders and maintain clinical independence while the group centralizes administrative and financial functions.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2022

2021

Similar deals in Healthcare & Pharma

List of similar M&A transactions (Date, Acquirer, Target, Country, Sector, Deal Context)
Date	Acquirer	Target	Country	Sector	Deal Context
07/2022	LATOUR CAPITAL	PHARMACIE LAFAYETTE - GROUPE HYGIE31	FRANCE	Health Providers	Latour Capital and Bpifrance acquired a majority stake in Hygie31, the holding company of Pharmacie Lafayette, from Five Arrows (Rothschild & Co). The deal aims to accelerate the group's development in France and Europe through organic growth and an ambitious buy-and-build strategy
07/2022	ANDERA PARTNERS	GROUPE RESONANCE IMAGERIE	FRANCE	Health Providers	R�sonance Imagerie, a prominent French medical imaging group, has secured a major financing package from Andera MidCap, Ardian Private Debt, and Five Arrows Debt Partners. Established in 2011, the group currently operates a network of 15 centers across Paris, �le-de-France, and the Centre-Val-de-Loire region, managing 23 high-tech units including MRIs and scanners
06/2022	ARDIAN	SIMAGO	FRANCE	Health Providers	Ardian acquired a significant minority stake in Simago. The investment was designed to support the group's rapid "buy-and-build" strategy in a highly fragmented French market. Unlike traditional LBOs, the deal was structured to preserve the medical independence of the associate radiologists, who continue to hold the majority of the capital and voting rights alongside the founding management team
06/2022	TRITON PARTNERS	ESPERI CARE	FINLAND	Health Providers	Triton Partners, via its Triton Smaller Mid Cap Fund II, acquired a majority stake in Esperi Care Oy from a consortium of its former creditors, including Danske Bank, SEB, and Ilmarinen, which remain as minority shareholders
04/2022	GROUPE BRUXELLES LAMBERT	AFFIDEA	NETHERLANDS	Health Providers	The Brussels Lambert Group (GBL) has finalized the acquisition of a majority stake in Affidea, the European leader in diagnostic imaging and outpatient care, from B-FLEXION (family office), which is exiting the investment after eight years
02/2022	MEINE RADIOLOGIE	ALERIS - RADIOLOGY	SWEDEN	Health Providers	The divestment of Aleris' radiology arm to Meine Radiologie Holding (backed by EQT Infrastructure) marks a significant consolidation in the Nordic diagnostic imaging market. This transaction was executed in tandem with the sale of Aleris' primary care and rehab units to Praktikertjänst, as part of a broader strategic shift
01/2022	WREN HOUSE	VOYAGE CARE	UNITED KINGDOM	Health Providers	Partners Group and Duke Street agreed to sell 100% of Voyage Care to Wren House Infrastructure Management, following approximately seven years of joint ownership since the 2014 acquisition alongside management
12/2021	VIVALTO PARTNERS / IK PARTNERS / MACSF / ARKEA CAPITAL / BNP PARIBAS DEVELOPPEMENT	VIVALTO SANTÉ	FRANCE	Health Providers	Vivalto Santé completed its third LBO, with Vivalto Partners — Daniel Caille's newly created investment management vehicle — taking control of the group. IK Partners joined as a key new minority shareholder alongside a broad consortium of reinvesting French institutional investors and the Bpifrance-Mubadala sovereign duo
12/2021	RAMSAY HEALTH CARE	ELYSIUM HEALTHCARE	UNITED KINGDOM	Health Providers	Ramsay Health Care entered into a definitive agreement on December 13, 2021, to acquire 100% of the UK-based mental healthcare provider Elysium Healthcare from BC Partners to solidify its standing within the specialized British clinical landscape
11/2021	CERBA HEALTHCARE	LABEXA	FRANCE	Health Providers	Cerba HealthCare acquired Labexa following a competitive auction process managed by Oddo BHF, beating out its main rival Biogroup. The acquisition allows Cerba to significantly strengthen its footprint in the French "Nouvelle-Aquitaine" region

REFERENCES

Valuation range: EV 500M - 1.5b EUR

Revenue range: 100M - 200M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of SEVETYS by EURAZEO are reserved for mynth community members. Register for free to unlock full data.

Authors: verified mynth contributor (mynth data is contributed by M&A / PE professionals and systematically cross-verified with private deal documents and official press releases).

Press release: view release

Acquirer: eurazeo